Sprague et al. conducted a 12-week randomized, double-blind, placebo-controlled trial that evaluated the efficacy of extended-release calcifediol in 78 patients with CKD, parathyroid hormone > 70 pg/mL and serum total 25(OH)D < 30 ng/mL [17]. Here, PTH is linked to chronic kidney disease.